NasdaqGS:IPHS

Stock Analysis Report

Executive Summary

Innophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets.

Snowflake

Fundamentals

Average dividend payer with moderate growth potential.


Similar Companies

Share Price & News

How has Innophos Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.6%

IPHS

0.2%

US Chemicals

0.4%

US Market


1 Year Return

3.6%

IPHS

-5.4%

US Chemicals

6.9%

US Market

Return vs Industry: IPHS exceeded the US Chemicals industry which returned -5.4% over the past year.

Return vs Market: IPHS underperformed the US Market which returned 6.9% over the past year.


Shareholder returns

IPHSIndustryMarket
7 Day11.6%0.2%0.4%
30 Day2.6%-2.1%-1.1%
90 Day27.6%-1.7%-0.5%
1 Year10.5%3.6%8.4%-5.4%9.3%6.9%
3 Year-1.1%-14.8%40.5%14.9%45.8%36.4%
5 Year-22.6%-39.2%43.0%12.2%62.9%45.1%

Price Volatility Vs. Market

How volatile is Innophos Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innophos Holdings undervalued compared to its fair value and its price relative to the market?

23.92x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: IPHS ($35.35) is trading above our estimate of fair value ($18.23)

Significantly Undervalued: IPHS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IPHS is poor value based on its PE Ratio (23.9x) compared to the Chemicals industry average (19x).

PE vs Market: IPHS is poor value based on its PE Ratio (23.9x) compared to the US market (17.6x).


Price to Earnings Growth Ratio

Low PEG Ratio: IPHS is good value based on its PEG Ratio (0.6x)


Price to Book Ratio

PB vs Industry: IPHS is overvalued based on its PB Ratio (2x) compared to the US Chemicals industry average (2x).


Next Steps

Future Growth

How is Innophos Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

37.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPHS's forecast earnings growth (37.8% per year) is above the savings rate (2.7%).

Earnings vs Market: IPHS's earnings (37.8% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: IPHS's revenue is expected to decline over the next 3 years (-0.07% per year).

High Growth Revenue: IPHS's revenue is forecast to decline over the next 3 years (-0.07% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if IPHS's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Innophos Holdings performed over the past 5 years?

-18.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IPHS's earnings have declined by -18.3% per year over the past 5 years.

Accelerating Growth: IPHS's earnings growth over the past year (65.6%) exceeds its 5-year average (-18.3% per year).

Earnings vs Industry: IPHS earnings growth over the past year (65.6%) exceeded the Chemicals industry -2.9%.


Return on Equity

High ROE: IPHS's Return on Equity (8.6%) is considered low.


Return on Assets

ROA vs Industry: IPHS's Return on Assets is below or equal to the Chemicals industry average last year.


Return on Capital Employed

ROCE Improving: IPHS's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is Innophos Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IPHS's short term assets ($340.5M) exceeds its short term liabilities ($119.3M)

Long Term Liabilities: IPHS's short term assets (340.5M) do not cover its long term liabilities (411.7M)


Debt to Equity History and Analysis

Debt Level: IPHS's debt to equity ratio (98.4%) is considered high

Reducing Debt: IPHS's debt to equity ratio has increased from 29.2% to 98.4% over the past 5 years.

Debt Coverage: IPHS's debt is well covered by operating cash flow (24.2%).

Interest Coverage: IPHS's interest payments on its debt are well covered by EBIT (4.5x coverage).


Balance Sheet

Inventory Level: IPHS has a high level of physical assets or inventory.

Debt Coverage by Assets: IPHS's debt is covered by short term assets (assets are 1.020000x debt).


Next Steps

Dividend

What is Innophos Holdings's current dividend yield, its reliability and sustainability?

5.43%

Current Dividend Yield


Dividend Yield vs Market

company5.4%marketbottom25%1.4%markettop25%3.7%industryaverage2.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: IPHS's dividend (5.43%) is higher than the bottom 25% of dividend payers in the US market (1.45%).

High Dividend: IPHS's dividend (5.43%) is in the top 25% of dividend payers in the US market (3.73%)

Stable Dividend: IPHS's dividends per share have been stable in the past 10 years.

Growing Dividend: IPHS's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (129.9%), IPHS's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of Innophos Holdings's salary, the management and board of directors tenure and is there insider trading?

2.4yrs

Average management tenure


CEO

Kim Mink (59yo)

3.8yrs

Tenure

US$3,353,966

Compensation

Dr. Kim Ann Mink, Ph.D., has been the Chief Executive Officer and President at Innophos Holdings Inc. since December 14, 2015. Dr. Mink serves as the President of CanStates Holdings, Inc. She has been a Di ...


CEO Compensation Analysis

Compensation vs. Market: Kim's total compensation ($USD3.35M) is about average for companies of similar size in the US market ($USD2.69M).

Compensation vs Earnings: Kim's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.4yrs

Average Tenure

59yo

Average Age

Experienced Management: IPHS's management team is considered experienced (2.4 years average tenure).


Board Age and Tenure

7.2yrs

Average Tenure

63yo

Average Age

Experienced Board: IPHS's board of directors are considered experienced (7.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Mark Feuerbach (60yo)

    Chief Financial Officer

    • Tenure: 0.6yrs
    • Compensation: US$752.26k
  • Kim Mink (59yo)

    Chairman of the Board

    • Tenure: 3.8yrs
    • Compensation: US$3.35m
  • James Testa (71yo)

    Assistant Secretary

    • Tenure: 0yrs
  • Sherry Duff (51yo)

    Senior VP and Chief Marketing & Technology Officer

    • Tenure: 3.3yrs
    • Compensation: US$724.63k
  • Yasef Murat (64yo)

    Senior Manufacturing Fellow

    • Tenure: 2.4yrs
    • Compensation: US$570.29k
  • Mark Santangelo (61yo)

    Senior Vice President of Manufacturing

    • Tenure: 2.4yrs
    • Compensation: US$776.54k
  • Josh Horenstein (42yo)

    Senior VP

    • Tenure: 3.6yrs
    • Compensation: US$814.35k
  • Amy Hartzell (43yo)

    Senior Vice President of Supply Chain & Purchasing

    • Tenure: 2.4yrs
    • Compensation: US$537.56k
  • William Dunworth (43yo)

    VP, Corporate Controller & Chief Accounting Officer

    • Tenure: 1yrs

Board Members

  • John Steitz (60yo)

    Independent Director

    • Tenure: 10.7yrs
    • Compensation: US$209.64k
  • Karen Osar (70yo)

    Independent Director

    • Tenure: 12yrs
    • Compensation: US$198.19k
  • Gary Cappeline (69yo)

    Independent Director

    • Tenure: 12.8yrs
    • Compensation: US$234.82k
  • Bob Zatta (69yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$208.05k
  • Peter Thomas (63yo)

    Lead Independent Director

    • Tenure: 1.5yrs
    • Compensation: US$218.76k
  • Linda Myrick (63yo)

    Independent Director

    • Tenure: 13yrs
    • Compensation: US$188.92k
  • Kim Mink (59yo)

    Chairman of the Board

    • Tenure: 3.8yrs
    • Compensation: US$3.35m
  • Jane Hilk (59yo)

    Director

    • Tenure: 0.9yrs
    • Compensation: US$10.87k

Company Information

Innophos Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innophos Holdings, Inc.
  • Ticker: IPHS
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: US$690.730m
  • Shares outstanding: 19.54m
  • Website: https://www.innophos.com

Number of Employees


Location

  • Innophos Holdings, Inc.
  • 259 Prospect Plains Road
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IPHSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2006
HQ9DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2006
IPHS *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNNov 2006

Biography

Innophos Holdings, Inc., together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Healt ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 23:53
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.